Bioharvest announces sales of flagship product vinia now exceed $50 million usd

Commercial success of vinia validates the power of bioharvest's patented botanical synthesis technology to produce valuable plant-based compounds at industrial scale vancouver, british columbia and rehovot, israel--(newsfile corp. - february 18, 2025) - bioharvest sciences inc. , (nasdaq: bhst) (fse: 8mv0) ("bioharvest" or "the company"), a company pioneering its patented botanical synthesis technology process, today announced that its red grape cell composition - known commercially as vinia® - has now exceeded $50 million usd in cumulative sales with the vast majority of sales occurring since launching in the us less than 4 years ago. vinia®, a red grape cell-based supplement, is produced by bioharvest's proprietary botanical synthesis platform technology.
BHST Ratings Summary
BHST Quant Ranking